We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > PTx

News List

Leukine® is beneficial to patients with mild-to-moderate Alzheimer’s, finds study europeanpharmaceuticalreview
March 26, 2021
In a Phase II trial, Leukine® (sargramostim) significantly reduced biomarkers of neurodegeneration and improved cognitive function.
New partnership to explore potential biodefence applications for FX-06 europeanpharmaceuticalreview
March 08, 2021
Under a licensing and collaboration agreement, Partner Therapeutics will evaluate whether FX-06 could be used to treat multiple biothreats of interest to the US Government.
Leukine Trial in Hospitalized COVID-19 Patients Meets Primary Endpoint americanpharmaceuticalreview
March 03, 2021
Partner Therapeutics (PTx) announced top-line results of the investigator-led SARPAC (Sargramostim in Patients with Acute Hypoxic Respiratory Failure and Acute COVID-19) study of inhaled Leukine® (sargramostim, yeast-derived recombinant human GM-CSF) ...
PTx Announces Contract with DOD for Leukine for COVID-19 Associated Acute Hypoxemia americanpharmaceuticalreview
August 12, 2020
Partner Therapeutics (PTx) anounced a $35 million milestone-based Other Transaction Agreement (OTA) with the U.S. Department of Defense (DOD).